Application of viper venom hemocoagulase in preparation of medicine for reversing anticoagulant effect of blood coagulation factor Xa inhibitor

A technology for coagulation factor and anticoagulation, applied in the field of medicine, can solve the problem of inability to reverse the anticoagulation effect of coagulation factor Xa inhibitor, and achieve the effect of reversing the antagonism

Pending Publication Date: 2022-07-01
ZHAOKE PHARMA HEFEI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it is not suitable for bleeding symptoms caused clinically by rivaroxaban
The research results of this literature show that

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of viper venom hemocoagulase in preparation of medicine for reversing anticoagulant effect of blood coagulation factor Xa inhibitor
  • Application of viper venom hemocoagulase in preparation of medicine for reversing anticoagulant effect of blood coagulation factor Xa inhibitor
  • Application of viper venom hemocoagulase in preparation of medicine for reversing anticoagulant effect of blood coagulation factor Xa inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 The reversal effect of Solejuan on the anticoagulant effect of FXa inhibitor

[0028] 1. Test materials

[0029] drug:

[0030] Slounase: Snake Venom Hemocoagulase Injection (CDE has confirmed its name), 1U / ml*10 bottles, provided by Hong Kong Lee's Pharmaceutical Factory on June 10, 2021.

[0031] Rivaroxaban: 20 mg, tablet, from Michigan Medicine B2 Pharmacy, manufactured by Janssen Pharmaceuticals, Inc., Lot No. 20MG441.

[0032] Apixaban: 5 mg tablets were obtained from Michigan Medicine B2 Pharmacy, manufactured by Bristol-Myers Squibb Company / Pfizer, Lot: ABU1445S.

[0033] Enoxaparin: 30 mg syringe, obtained from Michigan Medicine B2 Pharmacy, manufactured by Amphastar Pharmaceuticals, Inc., Lot: E0066LO.

[0034] Reagent preparation:

[0035] Rivaroxaban: dissolved in 1:1 DMSO:H 2 O, diluted in blood to final concentrations of 100 ng / mL, 250 ng / mL, 500 ng / mL and 7 ug / mL. The dose is selected according to the patient's blood concentration and high d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of viper venom hemocoagulase in preparation of a medicine for reversing the anticoagulation effect of a blood coagulation factor Xa inhibitor. According to the research on the ability of tachyletrickle belonging to viper venom hemocoagulase to reverse the anticoagulant effect of the blood coagulation factor Xa inhibitor as a hemostatic bypass agent, the tachyletrickle can reverse the anticoagulant effect of the blood coagulation factor Xa inhibitor in a dose-dependent manner, and thrombus formation in human blood can be completely recovered. The Trickle is confirmed to reverse the treatment potential of the anticoagulation effect of the blood coagulation factor Xa inhibitor clinically used at present, and a new rescue treatment means is provided for bleeding caused by the blood coagulation factor Xa inhibitor.

Description

technical field [0001] The invention belongs to the field of medicine, and particularly relates to the application of viper venom hemagglutinase in the preparation of a medicine for reversing the anticoagulation effect of a coagulation factor Xa inhibitor. Background technique [0002] Coagulation factor Xa (Factor Xa, FXa) is a key regulator in the anticoagulation cascade, which can promote thrombosis. In recent years, FXa inhibitors have become a hot spot in the research and development of anticoagulant drugs for the prevention and treatment of various acute and chronic thromboembolic diseases. Xabans are direct, highly selective and competitive factor Xa inhibitors that inhibit favorable and fibrin-bound factor Xa activity as well as prothrombin activity, thereby interfering with coagulation at the junction of the intrinsic and extrinsic coagulation pathways Cascade reaction, including rivaroxaban, apixaban, edoxaban. Heparin has a good anticoagulant effect in vivo and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/48A61P7/02
CPCA61K38/4833C12Y304/21005A61P7/02
Inventor 日合曼·艾迪力戴向荣陈程李小羿
Owner ZHAOKE PHARMA HEFEI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap